A systematic review and meta‐analysis of cell‐free DNA testing for detection of fetal sex chromosome aneuploidy
Prenatal Diagnosis · 2023
DOI: 10.1002/pd.6298 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Prenatal Diagnosis, 2023. Verfasst von Matthew A Shear und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NICHD NIH HHS, NHGRI NIH HHS.
Abstract (Originalsprache)
Objectives
The aim was to determine the accuracy of cell‐free DNA testing (cfDNA) for detecting sex chromosome aneuploidies (SCA) in singleton pregnancies.
Methods
A systematic review and meta‐analysis was performed to assess cfDNA accuracy for prenatal detection of 45,X, 47,XXY, 47,XXX and 47,XYY. Inclusion was restricted to studies published between January 2010 and December 2021 reporting both cfDNA and confirmatory diagnostic test results.
Results
For 45,X, the sensitivity was 98.8% (95%CI 94.6%–100%), specificity 99.4% (95%CI 98.7%–99.9%) and positive predictive value (PPV) 14.5% (95%CI 7.0%–43.8%). For 47,XXY, the sensitivity was 100% (95%CI 99.6%–100%), specificity 100% (95%CI 99.9%–100%) and PPV 97.7% (95%CI 78.6%–100%). For 47,XXX, the sensitivity was 100% (95%CI 96.9%–100%), specificity 99.9% (95%CI 99.7%–100%) and PPV 61.6% (95%CI 37.6%–95.4%). For 47,XYY, the sensitivity was 100% (95%CI 91.3%–100%), specificity 100% (95% CI 100%–100%) and PPV 100% (95%CI 76.5%–100%). All four SCAs had estimated negative predictive values (NPV) exceeding 99.99%, though false negatives were reported.
Conclusions
This analysis suggests that cfDNA is a reliable screening test for SCA, though both false negatives and false positives were reported. These estimates of test performance are derived from pregnancies at high pretest risk for aneuploidy, limiting the generalisability to average risk pregnancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, California, USA.
- Department of Pediatrics, Division of Medical Genetics, University of California, San Francisco, California, USA.
- Department of Gynecology and Obstetrics, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Department of Medicine, University of California, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
- Institute of Human Genetics, University of California, San Francisco, California, USA.
ORCID-Profile: Matthew A Shear, Kate Swanson, Angie C Jelin, Teresa N Sparks
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
- NHGRI NIH HHS
Zitieren
APA
Shear, M. A., Swanson, K., Garg, R., Jelin, A. C., Boscardin, J., Norton, M. E., & Sparks, T. N. (2023). A systematic review and meta‐analysis of cell‐free DNA testing for detection of fetal sex chromosome aneuploidy. Prenatal Diagnosis. https://doi.org/10.1002/pd.6298
Vancouver
Shear MA, Swanson K, Garg R, Jelin AC, Boscardin J, Norton ME, et al. A systematic review and meta‐analysis of cell‐free DNA testing for detection of fetal sex chromosome aneuploidy. Prenatal Diagnosis. 2023. doi:10.1002/pd.6298
BibTeX
@article{Shear2023,
author = {Shear, Matthew A and Swanson, Kate and Garg, Ria and Jelin, Angie C and Boscardin, John and Norton, Mary E and Sparks, Teresa N},
title = {A systematic review and meta‐analysis of cell‐free DNA testing for detection of fetal sex chromosome aneuploidy},
journal = {Prenatal Diagnosis},
year = {2023},
doi = {10.1002/pd.6298}
}
EUVIMED